Solrikitug not checked

Uniquity One (UNI) · NSI-8226

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
4 in total · 1 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
Tested for
COPD, Eosinophilic Esophagitis (EoE)
Main trialPhase 2
“A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).”In the company’s words, NCT06496620 on ClinicalTrials.gov
Other names
NSI-8226

Other drugs for COPD

All 55 drugs for COPD

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 23 Sep 2026 A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Phase 2Active, not recruiting 30 Apr 2027 A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2Completed 6 Jul 2026 A Study to Evaluate Solriktug in Adult Participants With Asthma
Phase 1Completed 2 Feb 2026 A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Solrikitug

Following is part of Solo: you see every change to Solrikitug the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in